OBJECTIVES: Tobacco smoking is one of the principal risk factors for cancer, respiratory disease, and cardiovascular disease. According to research reported by the WHO, the prevalence of current smokers in Russia in 2009 was 39%, and one-third of those who smoked in the past 12-month had made an attempt to quit. This study is aimed to assess co-morbidity, quality of life (QOL), work productivity loss, and resource utilization in Russian urban adults attempting to quit smoking. METHODS: Patients' self-reported data were collected from 2011 National Health and Wellness Survey (NHWS). Survey represented major urban areas in Russia. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of work productivity was measured by the Work Productivity and Activity Impairment instrument. Resource utilization was measured by health care provider, ambulance request and hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 6,092 (60.6%) had ever smoked cigarettes (38.2% current smokers, 43.5% former smokers, 16.2% smokers trying to quit smoking and 2.1% no smokers-in process to quit). Average age of attempters was 39.5 years. Attempters group reported more co-morbidities (headache 60%, sleep difficulties 44%, insomnia 37%, heartburn 36%, pain 32%, depression 29%), lower mean scores of MCS (41.7 vs. 44.7), more number of visits to health care providers (4.9 vs. 4.2), and a higher absenteeism (5.5% vs. 3.8%) over the past 6 months (absenteeism for last week) compared to those who never smoked. Furthermore, individuals attempting to quit group reported 26.6% work productivity loss compared to 22.3% in those who never smoked. All mentioned differences were statistically significant (p<0.05). CONCLUSIONS: In Russia, attempters to quit smoking suffer from impairment in mental QOL, work productivity loss and more co-morbidities. Findings indicate there is still an unmet need in individuals attempting to quit.
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TRENDS OF UTILIZATION OF AND SPENDING ON ANTI-TUBERCULOSIS MEDICATIONS IN THE UNITED STATES MEDICAID PROGRAM FROM 1991 TO 2011
Alahmari AK 1 , Aldawsari MF 1 , Luder HR 1 , Wigle PR 1 , Kelton CM 2 , Guo JJ 1 1 University of Cincinnati College of Pharmacy, Cincinnati, OH, USA, 2 University of Cincinnati College of Business, Cincinnati, OH, USA OBJECTIVES: Tuberculosis (TB) is a serious infectious disease which affects the respiratory system. In 2011, 10,521 new TB cases were reported in the U.S. The anti-TB drug class contains both first-and second-line treatments, with the firstline regimen considered the skeleton of TB eradication. The purpose of the current study was to describe the trends in utilization of and spending on anti-TB drugs generally and individual anti-TB medications in the U.S. Medicaid Program. METHODS: A retrospective, descriptive analysis was conducted to examine the trends in utilization of and spending on anti-TB medications, using the national Medicaid pharmacy files from 1991 quarter 1 through 2011 quarter 2. Study drugs included isoniazid, rifampin, pyrazinamide, and ethambutol (firstline therapies); and cycloserine, kanamycin, streptomycin, amikacin, capreomycin, moxifloxacin, rifater, rifamate, thioamides, paser, rifapentine and rifabutin (second-line therapies). Quarterly prescription numbers and reimbursement amounts were calculated over time by summing data for individual drug products. The quarterly per-prescription reimbursement as a proxy for drug price was computed for each drug. RESULTS: Total Medicaid utilization of anti-TB drugs rose by 43% from 151,344 in 1991 to 216,271 in 2011. Utilization of the first-line drugs increased from 47,348 in 1991 to 65,482 in 1993, stayed at this level for 4 years, and then decreased to an average of 43,245 per year. Medicaid reimbursement for anti-TB medications increased 246% ($6.5 million to $22.4 million) between 1991 and 2011. Prices for second-line drugs were higher than those for traditional drugs due to absence of generic availability for the newer drugs. In 2011, reimbursement for second-line agents was 10 times that for first-line therapies. CONCLUSIONS: Utilization of anti-TB drugs was closely related to disease incidence. The rise in spending on secondline agents may be due to increased usage for other indications along with rising prices. An effective management program for anti-TB drug prescribing might be helpful for Medicaid.
PRS61 EUROPEAN EX-FACTORY PRICE DEVELOPMENT FOR GLOBAL PHARMACEUTICAL COMPANIES IN THE CONTEXT OF THE INTERNATIONAL PRICE REFERENCE (IPR) FRAMEWORK. IMPACT OF THE GERMAN HEALTH CARE REFORM (AMNOG) ON THE EUROPEAN PRICE DEVELOPMENT FOR INNOVATIVE PHARMACEUTICALS
Ernst F Santen GmbH, Munich, Germany OBJECTIVES: To evaluate pharmaceutical pricing in the EU with a focus of costcontainment due to International Price Reference (IPR) in the context of the German AMNOG on pricing in Europe. METHODS: Qualitative research identified guidelines for international price reference from each national reimbursement body (focusing on 10 major EU countries). Reimbursement submissions and results of price negotiations per country were also reviewed to gain insight into the application of pricing guidelines. Findings are based on review of the guidelines, selected appraisals and interviews with national payers in Germany, France and UK. RESULTS: In consideration of existing European price differences, high-price countries have so far increasingly attempted to also lower their pharmaceutical prices: preferably with different cost containment policies and measurements and in addition referencing low-price countries in international price reference (IPR). In both situations, an international downward effect on pricing threatens to happen for global pharmaceutical companies investing in Europe. This creates a European pricing and reimbursement network of connections of countries referencing each other with the tendency to develop a standard price across European countries. Germany is directly price referenced by more than 15 countries and indirectly referenced by around 5 countries. What impact on European pricing the change from the previously free pricing and full reimbursement of patented drug prices in Germany really has, after the implementation of the AMNOG, is quantitatively hard to assess. CONCLUSIONS: If Germany will follow more strictly the international price referencing in the future for innovative drugs based on the AMNOG process, it will lose anchor function in European pricing with an overall international downward effect on the European pricing for innovative pharmaceuticals.
PRS62 THE DISEASE BURDEN OF PEDIATRIC ATOPIC DERMATITIS ACROSS 12 COUNTRIES IN THE ASIA PACIFIC REGION
Azmi S 1 , Low W 2 1 Veras Research, Kelana Jaya, Malaysia, 2 Azmi Burhani Consulting, Kelana Jaya, Malaysia OBJECTIVES: Atopic dermatitis (AD), also known as eczema, is a common chronic skin condition in childhood that has negative impact on both patients and their families. A survey was conducted to evaluate the disease burden, financial and quality of life impact of moderate to severe AD across 12 countries in the Asia Pacific region. In this analysis, we examine the disease burden of pediatric AD by country. METHODS: A cross sectional survey was conducted in Australia, China, Hong Kong, India, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam in January, 2011. An online questionnaire was administered to 1028 parents with children diagnosed with moderate to severe AD (aged 1 t-16 years). For the purpose of analysis, respondents were categorized according to country, disease severity based on the Nottingham Eczema Severity Score, and age group. RESULTS: In the population sampled, there were 27% infants (aged less than 4 years) and 73% children (4 -16 years old). Approximately 60% of the respondents from all countries reported moderate AD. Infants and children with moderate AD experienced fewer flare-ups per year (median=5) compared to children with severe AD (median=7). There was no difference in overall flare-up duration (5 days) between moderate and severe AD. The overall percentage of children with more than 6 flare-ups per year was 41%, more often seen in (≥45%) in Singapore, Australia, Thailand, Taiwan, and Hong Kong. Common associated conditions with AD were food allergies, asthma and rhinitis. CONCLUSIONS: Results of the survey showed that moderate to severe AD is a common condition affecting infants and children with an average of 5-7 flare-ups per year lasting an average of 5 days. The burden of AD is higher among more developed countries in the Asia Pacific region.
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